Recent studies explore the evolving use of radiation in patients with solid tumors

This news section offers Cancer readers timely information on events, public policy analysis, and topical issues. In this issue, radiotherapy may benefit select patients with kidney cancer, but more trials are still needed to determine its role in relation to standard treatments. In addition, the FDA has granted full approval to heterobifunctional protein degrader vepdegestrant for adults with ER‐positive, HER2‐negative, ESR1 ‐mutated advanced or metastatic breast cancer, and short‐term testosterone replacement therapy improved sexual function after radical prostatectomy in men with low‐grade prostate cancer.